Table 1.
Descriptive Characteristics and Results from the Cox Proportional Hazard Regression Analyses for the Association of Patient and Tumor Characteristics with Disease-Specific Survival and Overall Survival
| Hazard ratio (95% confidence interval) | |||
|---|---|---|---|
| n (%) | Disease-specific survival | Overall survival | |
| Patient characteristics | |||
| Age at diagnosis (years) | |||
| Median age (range) | 62 (18–99) | 1.05 (1.04–1.05) | 1.05 (1.05–1.06) |
| Sex | |||
| Female | 1403 (58.2%) | Reference | Reference |
| Male | 1008 (41.8%) | 1.11 (0.93–1.32) | 1.26 (1.08–1.46) |
| Race | |||
| White | 1859 (77.1%) | Reference | Reference |
| Black | 170 (7.1%) | 0.88 (0.62–1.24) | 1.03 (0.78–1.37) |
| Asian/Pacific Islander | 354 (14.7%) | 0.80 (0.61-1.05) | 0.84 (0.67–1.05) |
| American Indian/Alaska Native | 28 (1.2%) | 0.70 (0.23–2.20) | 1.10 (0.49–2.46) |
| Ethnicity | |||
| Non-Hispanic | 1841 (76.4%) | Reference | Reference |
| Hispanic | 570 (23.6%) | 1.18 (0.95–1.46) | 1.08 (0.89–1.31) |
| County-level median household income | |||
| Less than $60,000 | 611 (25.3%) | Reference | Reference |
| $60,000–64,999 | 492 (20.4%) | 1.09 (0.84–1.41) | 1.01 (0.81–1.26) |
| $65,000–69,999 | 378 (15.7%) | 0.97 (0.73–1.31) | 1.04 (0.81–1.33) |
| $70,000–74,999 | 159 (6.6%) | 1.21 (0.84–1.76) | 1.13 (0.82–1.56) |
| More than $75,000 | 771 (32.0%) | 0.99 (0.78–1.26) | 0.90 (0.73–1.11) |
| County type | |||
| Metropolitan | 2187 (90.7%) | Reference | Reference |
| Nonmetropolitan | 224 (9.3%) | 0.99 (0.72–1.38) | 1.02 (0.78–1.34) |
| Tumor characteristics | |||
| Histological subtype | |||
| Papillary thyroid cancer | 2073 (86.0%) | Reference | Reference |
| Follicular thyroid cancer | 256 (10.6%) | 0.68 (0.52–0.89) | 0.87 (0.69–1.08) |
| Oncocytic carcinoma of the thyroid | 82 (3.4%) | 1.06 (0.74–1.51) | 1.10 (0.80–1.50) |
| Size of primary tumor | |||
| Less than 2 cm | 575 (23.9%) | Reference | Reference |
| Between 2–4cm | 936 (38.8%) | 1.47 (1.11–1.94) | 1.42 (1.14–1.78) |
| Greater than 4 cm | 900 (37.3%) | 2.91 (2.24–3.79) | 2.41 (1.94–3.00) |
| Bone metastases | |||
| No | 1956 (81.1%) | Reference | Reference |
| Yes | 455 (18.9%) | 1.51 (1.23–1.85) | 1.37 (1.14–1.64) |
| Brain metastases | |||
| No | 2355 (97.7%) | Reference | Reference |
| Yes | 56 (2.3%) | 3.01 (2.07-4.38) | 2.71 (1.91–3.84) |
| Lung metastases | |||
| No | 1599 (66.3%) | Reference | Reference |
| Yes | 812 (33.7%) | 2.06 (1.73–2.45) | 1.67 (1.44–1.94) |
| Liver metastases | |||
| No | 2355 (97.7%) | Reference | Reference |
| Yes | 56 (2.3%) | 1.56 (1.04–2.36) | 1.28 (0.86–1.90) |